Variability of crop calendar stage dates

There are no author-identified significant results in this report

Application of semiconductor industry cleaning technologies for Genesis sample collectors

Genesis array collectors recovered after the sub-nominal landing have been exposed to particulate and molecular contamination. In this study, semiconductor industry based cleaning technologies are being evaluated for their efficacy in contaminant removal

Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)

Purpose: To assess the role of participant-reported symptoms on long-term adherence to preventive therapy in the United Kingdom sample of the International Breast Cancer Intervention Study (IBIS-I). IBIS-I was a randomized controlled trial that investigated the effectiveness of tamoxifen in reducing the risk of breast cancer among women at increased risk of the disease. Participants and Methods: Women were randomly assigned to tamoxifen versus placebo (20 mg/day; n = 4,279). After 456 exclusions, 3,823 women were included in this analysis. Adherence (< 4.5 years or ≥ 4.5 years) was calculated using data from six monthly clinical visits. Analyses were adjusted for age, Tyrer-Cuzick risk, smoking, use of hormone replacement therapy, menopausal status, baseline menopausal symptoms, and treatment. Results: Overall, 69.7% of women were adherent for at least 4.5 years (tamoxifen: 65.2% v placebo: 74.0%; P .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management

Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial

Supported in part by Cancer Research UK (C569/A5032) and the National Health and Medical Research Council Australia (GNT300755, GNT569213), and in part by AstraZeneca, who also provided anastrozole and matching placebo. This study was sponsored by Queen Mary University of London, London, United Kingdom

Experimental L-band SST satellite communications/surveillance terminal study. Volume 3 - Communications/surveillance analysis

Analysis of surveillance and communications functions of L band air traffic control satellite syste

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

Licensed under a Creative Commons Attribution Non-Commercial Share Alike Licens